Condition (MeSH)
Solitary Fibrous Tumors
ClinicalTrials.gov lists 36 trials for Solitary Fibrous Tumors or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 11.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
10 of the 36 trials are tagged with Solitary Fibrous Tumors itself; the rest are tagged with a narrower condition beneath it.
When did Solitary Fibrous Tumors trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 3
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2020 | 2 |
| 2019 | 1 |
| 2018 | 1 |
| 2017 | 1 |
| 2016 | 3 |
| 2015 | 1 |
| 2014 | 2 |
| 2013 | 1 |
| 2010 | 3 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 3 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Solitary Fibrous Tumors trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 3 |
| Phase 2 | 25 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 4 |
How many Solitary Fibrous Tumors trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 26 |
| Terminated | 5 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Solitary Fibrous Tumors trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 11 |
| Italian Sarcoma Group | 2 |
| Epkin | 1 |
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Papworth Hospital NHS Foundation Trust | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Solitary Fibrous Tumors? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cediranib | 3 |
| PEMBROLIZUMAB | 2 |
| Trabectedin | 2 |
| DASATINIB | 2 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Cisplatin 1 | 7 |
| Pemetrexed Disodium Injection | 4 |
| Adjuvant Therapy | 3 |
| Gemcitabine/Gemzar | 2 |
| Arm 3: Dacarbazine | 2 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Solitary Fibrous Tumors trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 56 | 6 |
| Pleural effusion | 38 | 5 |
| Nausea | 31 | 4 |
| Dehydration | 28 | 6 |
| Vomiting | 24 | 3 |
Showing 5 of 10 adverse events.
Which publications cover Solitary Fibrous Tumors? (13)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial. | The Lancet. Oncology | 2020 | Yes |
| Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial. | The Lancet. Oncology | 2019 | Yes |
| Solitary fibrous tumors: loss of chimeric protein expression and genomic instability mark dedifferentiation. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2015 | Yes |
| Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. | BMC cancer | 2015 | Yes |
| Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour. | European journal of cancer (Oxford, England : 1990) | 2014 | Yes |
Showing 5 of 13 publications.
Prevalence (1)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Solitary fibrous tumor | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: rare-disease identity.